Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

135.51USD
24 May 2019
Change (% chg)

$-2.53 (-1.83%)
Prev Close
$138.04
Open
$138.49
Day's High
$139.21
Day's Low
$135.44
Volume
804,946
Avg. Vol
604,767
52-wk High
$197.00
52-wk Low
$125.84

Latest Key Developments (Source: Significant Developments)

Harrow Health - Allergan Requested Damages Of More Than $7.2 Million In Lost Profits And $54 Million In Profit Disgorgement
Friday, 17 May 2019 

May 17 (Reuters) - Allergan plc ::HARROW HEALTH - ON MAY 15, ALLERGAN REQUESTED DAMAGES OF MORE THAN $7.2 MILLION IN LOST PROFITS AND $54 MILLION IN PROFIT DISGORGEMENT IN LAWSUIT AGAINST CO.HARROW HEALTH - ON MAY 16, JURY FOUND CO LIABLE FOR LOST PROFIT DAMAGES IN AMOUNT OF $48,500 AND ZERO DOLLARS FOR DISGORGED PROFITS.  Full Article

Allergan Declares Second Quarter 2019 Cash Dividend Of $0.74 Per Ordinary Share
Friday, 3 May 2019 

May 3 (Reuters) - Allergan plc ::ALLERGAN DECLARES SECOND QUARTER 2019 CASH DIVIDEND OF $0.74 PER ORDINARY SHARE.  Full Article

Appaloosa Comments On ISS Qualified Recommendation
Monday, 15 Apr 2019 

April 15 (Reuters) - Appaloosa::APPALOOSA COMMENTS ON ISS QUALIFIED RECOMMENDATION.APPALOOSA - URGE ALLERGAN SHAREHOLDERS TO VOTE FOR OUR PROPOSAL TO SEPARATE THE CHAIRMAN AND CEO ROLES.APPALOOSA - ISS’S RECOMMENDATION TO FORESTALL SEPARATION OF ALLERGAN’S CHAIRMAN, CEO ROLES IS A "MISUNDERSTANDING" OF REASONS FOR "UNDERPERFORMANCE".  Full Article

Allergan Is Reviewing Health Canada Notice To Suspend Co's Licences For Biocell Breast Implants
Friday, 5 Apr 2019 

April 4 (Reuters) - Allergan plc ::ALLERGAN IS CURRENTLY REVIEWING APRIL 4 HEALTH CANADA NOTICE OF ITS INTENT TO SUSPEND CO'S LICENCES FOR BIOCELL BREAST IMPLANTS - SPOKESWOMAN.ALLERGAN INTENDS TO RESPOND WITHIN THE DEADLINE PROVIDED BY HEALTH CANADA - SPOKESWOMAN.  Full Article

Appaloosa Says Files Supplemental Presentation On Allergan
Friday, 5 Apr 2019 

April 4 (Reuters) - Appaloosa::APPALOOSA SAYS FILES SUPPLEMENTAL PRESENTATION ON ALLERGAN.  Full Article

Health Canada Says Intend To Suspend Allergan's Biocell Breast Implants Licences As A Precautionary Measure
Thursday, 4 Apr 2019 

April 4 (Reuters) - Health Canada::INFORMATION UPDATE - HEALTH CANADA ADVISES ALLERGAN OF ITS INTENT TO SUSPEND ITS LICENCES FOR BIOCELL BREAST IMPLANTS AS A PRECAUTIONARY MEASURE.HEALTH CANADA - AS OF APRIL 4, BEEN NOTIFIED OF 28 CONFIRMED CANADIAN CASES OF BIA-ALCL, OF WHICH 24 (86%) INVOLVE ALLERGAN'S BIOCELL BREAST IMPLANT.HEALTH CANADA - REVIEWING INFORMATION ON SAFETY OF TEXTURED BREAST IMPLANTS, INCLUDES ANY NEW EVIDENCE PROVIDED BY ALLERGAN IN NEXT 15 CALENDAR DAYS.HEALTH CANADA - ENGAGING INTERNATIONALLY ON SAFETY OF BREAST IMPLANTS, INCLUDING RECENT MEETINGS WITH FRENCH REGULATOR AND FDA.HEALTH CANADA - IF SATISFACTORY RESPONSE IS NOT RECEIVED FROM ALLERGAN IN NEXT 15 CALENDAR DAYS, INTENTION TO SUSPEND BIOCELL MEDICAL DEVICE LICENCES.HEALTH CANADA - IN CONTACT WITH FRANCE ABOUT ITS DECISION TODAY TO SUSPEND SALE OF MACRO-TEXTURED BREAST IMPLANTS, POLYURETHANE-COATED BREAST IMPLANTS.HEALTH CANADA - ENTIRETY OF ITS SAFETY REVIEW OF BREAST IMPLANTS AND BIA-ALCL WILL BE AVAILABLE BY END OF APRIL.HEALTH CANADA SAYS STARTED A SECOND SAFETY REVIEW ON SYSTEMIC SYMPTOMS ASSOCIATED WITH BREAST IMPLANTS.HEALTH CANADA - RESULTS OF THE SECOND SAFETY REVIEW WILL BE MADE PUBLIC IN SUMMER 2019..  Full Article

Allergan Launches Juvéderm Volux - The Latest Evolution In Facial Filler Treatments
Thursday, 4 Apr 2019 

April 4 (Reuters) - Allergan plc ::ALLERGAN LAUNCHES JUVÉDERM® VOLUX - THE LATEST EVOLUTION IN FACIAL FILLER TREATMENTS FOR THOSE SEEKING A MORE DEFINED CHIN AND JAWLINE.  Full Article

Appaloosa Says Released Investor Presentation On Allergan
Monday, 25 Mar 2019 

March 25 (Reuters) - Allergan plc ::APPALOOSA STATEMENT REGARDING ALLERGAN PROXY FILING.APPALOOSA LP - STATEMENT IN RESPONSE TO ALLERGAN'S MARCH 22 PROXY FILING, INTENTION TO INSTALL INDEPENDENT CHAIRMAN AT NEXT CEO TRANSITION.APPALOOSA SAYS RELEASED INVESTOR PRESENTATION ON ALLERGAN.  Full Article

Allergan Says CEO Brenton Saunders' 2018 Total Compensation Was $6.6 Million
Saturday, 23 Mar 2019 

March 22 (Reuters) - Allergan plc ::ALLERGAN SAYS CEO BRENTON SAUNDERS' 2018 TOTAL COMPENSATION WAS $6.6 MILLION - SEC FILING.  Full Article

Allergan to Present New Data On Eye Implant Bimatoprost SR
Thursday, 14 Mar 2019 

March 14 (Reuters) - Allergan plc ::ALLERGAN TO PRESENT NEW DATA - "EXTENDED DURATION OF INTRAOCULAR PRESSURE (IOP) CONTROL WITH INTRACAMERAL BIMATOPROST SUSTAINED-RELEASE (SR) IMPLANT" -- HIGHLIGHTING CLINICAL ADVANCES AT THE AMERICAN GLAUCOMA SOCIETY ANNUAL MEETING.ALLERGAN PLC - US NDA SUBMISSION EXPECTED IN SECOND HALF OF 2019.  Full Article

UPDATE 3-Allergan CEO says company is urgently looking at all options to boost share price

May 7 Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.